Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.

被引：75

作者：

Tabernero, Josep

Van Cutsem, Eric

Bang, Yung-Jue

Fuchs, Charles S.

Wyrwicz, Lucjan

Lee, Keun Wook

Kudaba, Iveta

Garrido, Marcelo

Chung, Hyun Cheol

Salguero, Hugo Raul Castro

Mansoor, Wasat

Braghiroli, Maria Ignez Freitas Melro

Goekkurt, Eray

Chao, Joseph

Wainberg, Zev A.

Kher, Uma

Shah, Sukrut

Kang, SoonMo Peter

Shitara, Kohei

机构：

[1] Vall dHebron Univ Hosp, Barcelona, Spain

[2] Inst Oncol, Barcelona, Spain

[3] Univ Hosp Gasthuisberg, Leuven, Belgium

[4] Katholieke Univ Leuven, Leuven, Belgium

[5] Seoul Natl Univ, Coll Med, Seoul, South Korea

[6] Yale Canc Ctr, New Haven, CT USA

[7] M Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[8] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea

[9] Riga East Univ Hosp, Riga, Latvia

[10] Pontificia Univ Catolica Chile, Santiago, Chile

[11] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

[12] Hosp Enfermedad Comun Igss Zona 9, Guatemala City, Guatemala

[13] Christie NHS, Manchester, Lancs, England

[14] Univ Sao Paulo, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[15] Univ Canc Ctr Hamburg, Hamburg, Germany

[16] City Hope Comprehens Canc Ctr, Duarte, CA USA

[17] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[18] Merck & Co Inc, Kenilworth, NJ USA

[19] Merck & Co Inc, Rahway, NJ 07065 USA

[20] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 18期

关键词：

D O I：

10.1200/JCO.2019.37.18_suppl.LBA4007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA4007

引用

页数：2

共 50 条

[41] The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Rha, S. Y.
Kawazoe, A.
Bai, Y.
Xu, J.
Lonardi, S.
Metges, J-P.
Yanez Weber, P. E.
Wyrwicz, L. S.
Shen, L.
Ostapenko, Y. V.
Bilici, M.
Chung, H. C.
Shitara, K.
Qin, S.
van Cutsem, E.
Tabernero, J.
Li, K.
Shih, C-S.
Bhagia, P.
Janjigian, Y. Y.
ANNALS OF ONCOLOGY, 2023, 34 : S1521 - S1522
[42] Tislelizumab in combination with chemotherapy in Chinese patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer: Results from one cohort of an ongoing phase 2 study.
Bai, Yu-Xian
Li, En Xiao
Wang, Buhai
Yuan, Xianglin
Xu, Nong
Chen, Yunxin
Li, Xiang
Wang, Huanli
Xu, Jianming
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[43] Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma
Rha, S. Y.
Kawazoe, A.
Bai, Y.
Xu, J.
Lonardi, S.
Metges, J-P.
Weber, P. E. Yanez
Wyrwicz, L. S.
Shen, L.
Ostapenko, Y. V.
Bilici, M.
Chung, H. C.
Shitara, K.
Mahave, M.
van Cutsem, E.
Tabernero, J.
Xu, L.
Sharan, K. P.
Bhagia, P.
Janjigian, Y. Y.
ANNALS OF ONCOLOGY, 2024, 35 : S1453 - S1454
[44] Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-)181 study.
Kojima, Takashi
Muro, Kei
Francois, Eric
Hsu, Chih-Hung
Moriwaki, Toshikazu
Kim, Sung-Bae
Lee, Se-Hoon
Bennouna, Jaafar
Kato, Ken
Lin, Shen
Qin, Shi-Qui
Ferreira, Paula
Doi, Toshihiko
Adenis, Antoine
Enzinger, Peter C.
Shah, Manish A.
Wang, Ruixue
Bhagia, Pooja
Kang, S. Peter
Metges, Jean-Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[45] Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.
Chau, Ian
Bendell, Johanna C.
Calvo, Emiliano
-Davila, Rafael Santana
Arkenau, Hendrik-Tobias
Mi, Gu
Jin, Jin
Rege, Jessicca
Ferry, David
Herbst, Roy S.
Fuchs, Charles S.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[46] Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Kojima, Takashi
Shah, Manish A.
Muro, Kei
Francois, Eric
Adenis, Antoine
Hsu, Chih-Hung
Doi, Toshihiko
Moriwaki, Toshikazu
Kim, Sung-Bae
Lee, Se-Hoon
Bennouna, Jaafar
Kato, Ken
Shen, Lin
Enzinger, Peter
Qin, Shu-Kui
Ferreira, Paula
Chen, Jia
Girotto, Gustavo
de la Fouchardiere, Christelle
Senellart, Helene
Al-Rajabi, Raed
Lordick, Florian
Wang, Ruixue
Suryawanshi, Shailaja
Bhagia, Pooja
Kang, S. Peter
Metges, Jean-Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (35)
[47] Q-TWiST analysis of pembrolizumab or placebo plus chemotherapy for patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer in KEYNOTE-859.
Wyrwicz, Lucjan
Kalampoki, Vasiliki
Valderrama, Adriana
Ramakrishnan, Karthik
Young, Kate
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
[48] Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Fuchs, Charles S.
Denker, Andrew E.
Tabernero, Josep
Van Cutsem, Eric
Ohtsu, Atsushi
Lam, Baohoang
Koshiji, Minori
Bang, Yung-Jue
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[49] Clinical outcome of pembrolizumab in clinical studies for advanced gastric and gastroesophageal junction (G/GEJ) cancer
Muro, Kei
ANNALS OF ONCOLOGY, 2017, 28 : 35 - 35
[50] Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
Ohtsu, A.
Tabernero, J.
Bang, Y. -J.
Fuchs, C. S.
Sun, L.
Wang, Z.
Csiki, I.
Koshiji, M.
Van Cutsem, E.
ANNALS OF ONCOLOGY, 2015, 26 : 69 - 69

← 1 2 3 4 5 →